EUCTR2005-004499-19-IE进行中（未招募）1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder - L-000796568 Overactive Bladder Study
Merck Sharp & Dohme Ireland (Human Health) Limited0 个研究点开始时间: 2005年10月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Postmenopausal females (ages 40-74 inclusive) with predominantly urge urinary incontinence overactive bladder episodes. Patients must meet minimum eligibility requirements of average number of = 8 micturitions/day and average number of = 1 urge incontinence episode/day based on screening and run-in diary cards.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients must not suffer from diabetes insipidus, hyperglycemia, hypercalcemia, orthostatic hypotension or active/recurrent urinary tract infections (>6 episodes per year).
- •Patients must be willing to discontinue their current OAB medication therapy. Patients must not be taking any strong or moderate CYP3A4 inducers or inhibitors.
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-CZAllergan Inc.350
未知
3 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain.JPRN-jRCT2080221194Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate theSafety and Antiretroviral Activity of MK-0518 in Combination With an OptimizedBackground Therapy (OBT), Versus Optimized Background Therapy Alone, in HIVInfected Patients With Documented Resistance to at Least 1 Drug in Each of the 3Classes of Licensed Oral Antiretroviral Therapies - Safety, PK, and Efficacy of MK-0518 plus OBT vs OBT Alone in HIV+nspecified human immuno-deficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2005-005127-34-PTMerck Sharp & Dohme, Lda.366
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-ATAllergan Inc.350
进行中（未招募）
1 期
A global study completed at hospitals in US, Europe & Asia using an investigational drug (Perampanel) to research its safety & effectiveness in patients who are at least 2 years of age with Lennox-Gastaut SyndromeSeizures associated with Lennox-Gastaut Syndrome (LGS)MedDRA version: 20.0Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-002321-35-PLEisai Limited70